SCHEMBL2205367

SCHEMBL2205367

Cc1ccccc1-c1c(C(=O)O)n(CCOc2cccc(Cl)c2Cl)c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 4/20 0.69
CAMK2B Q13554 4/20 0.69
MARK2 Q7KZI7 4/20 0.69
MINK1 Q8N4C8 4/20 0.69
HIPK2 Q9H2X6 4/20 0.69
GSK3B P49841 3/20 0.69
SRPK1 Q96SB4 3/20 0.69
IRAK1 P51617 3/20 0.69
NEK4 P51957 3/20 0.69
MAP4K2 Q12851 3/20 0.69
TAOK1 Q7L7X3 3/20 0.69
HIPK4 Q8NE63 3/20 0.69
MAP3K20 Q9NYL2 3/20 0.69
CDC7 O00311 2/20 0.69
CDC42BPA Q5VT25 2/20 0.69
CAMK2G Q13555 2/20 0.69
CAMK2D Q13557 2/20 0.69
PIM3 Q86V86 2/20 0.69
PRKD2 Q9BZL6 2/20 0.69
EEF2K O00418 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204396 0.94 MARK3 (0.73) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2204280 0.90 MARK3 (0.56) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2204748 0.87 MARK3 (0.90) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL17044292 0.87 MARK3 (0.52) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL27780885 0.87 MARK3 (0.52) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2204657 0.85 MARK3 (0.63) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2202499 0.84 MARK3 (0.59) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2201257 0.82 MARK3 (1.00) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL2206423 0.81 MARK3 (0.94) MARK3CAMK2BMARK2MINK1HIPK2
SCHEMBL17044251 0.81 MARK3 (0.55) MARK3CAMK2BMARK2MINK1HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134685-B1 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS ABBVIE INC (US) 2015-09-02 EP claimed
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES 2011-10-27 US claimed
US-20090124616-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-05-14 US claimed
EP-2134685-B1 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS ABBVIE INC (US) 2015-09-02 EP disclosed
US-8853209-B2 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives ABBVIE INC. (US) 2014-10-07 US disclosed
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES 2011-10-27 US disclosed
US-7981888-B2 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives ABBOTT LABORATORIES (US) 2011-07-19 US disclosed
EP-2134685-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090124616-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
WO-2008130970-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124616-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2407/4885CAMK2B 941/4885MARK2 3389/4885
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MARK3 2407/4885CAMK2B 941/4885MARK2 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.